Using Artificial Intelligence to Improve the Accuracy of a Wrist-Worn, Noninvasive Glucose Monitor: A Pilot Study.

blood glucose self-monitoring diabetes mellitus microwaves noninvasive glucose monitoring radio frequency wearable electronic devices

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
17 May 2024
Historique:
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: aheadofprint

Résumé

Self-monitoring of glucose is important to the successful management of diabetes; however, existing monitoring methods require a degree of invasive measurement which can be unpleasant for users. This study investigates the accuracy of a noninvasive glucose monitoring system that analyses spectral variations in microwave signals. An open-label, pilot design study was conducted with four cohorts (N = 5/cohort). In each session, a dial-resonating sensor (DRS) attached to the wrist automatically collected data every 60 seconds, with a novel artificial intelligence (AI) model converting signal resonance output to a glucose prediction. Plasma glucose was measured in venous blood samples every 5 minutes for Cohorts 1 to 3 and every 10 minutes for Cohort 4. Accuracy was evaluated by calculating the mean absolute relative difference (MARD) between the DRS and plasma glucose values. Accurate plasma glucose predictions were obtained across all four cohorts using a random sampling procedure applied to the full four-cohort data set, with an average MARD of 10.3%. A statistical analysis demonstrates the quality of these predictions, with a surveillance error grid (SEG) plot indicating no data pairs falling into the high-risk zones. These findings show that MARD values approaching accuracies comparable to current commercial alternatives can be obtained from a multiparticipant pilot study with the application of AI. Microwave biosensors and AI models show promise for improving the accuracy and convenience of glucose monitoring systems for people with diabetes.

Sections du résumé

BACKGROUND UNASSIGNED
Self-monitoring of glucose is important to the successful management of diabetes; however, existing monitoring methods require a degree of invasive measurement which can be unpleasant for users. This study investigates the accuracy of a noninvasive glucose monitoring system that analyses spectral variations in microwave signals.
METHODS UNASSIGNED
An open-label, pilot design study was conducted with four cohorts (N = 5/cohort). In each session, a dial-resonating sensor (DRS) attached to the wrist automatically collected data every 60 seconds, with a novel artificial intelligence (AI) model converting signal resonance output to a glucose prediction. Plasma glucose was measured in venous blood samples every 5 minutes for Cohorts 1 to 3 and every 10 minutes for Cohort 4. Accuracy was evaluated by calculating the mean absolute relative difference (MARD) between the DRS and plasma glucose values.
RESULTS UNASSIGNED
Accurate plasma glucose predictions were obtained across all four cohorts using a random sampling procedure applied to the full four-cohort data set, with an average MARD of 10.3%. A statistical analysis demonstrates the quality of these predictions, with a surveillance error grid (SEG) plot indicating no data pairs falling into the high-risk zones.
CONCLUSIONS UNASSIGNED
These findings show that MARD values approaching accuracies comparable to current commercial alternatives can be obtained from a multiparticipant pilot study with the application of AI. Microwave biosensors and AI models show promise for improving the accuracy and convenience of glucose monitoring systems for people with diabetes.

Identifiants

pubmed: 38757895
doi: 10.1177/19322968241252819
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19322968241252819

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MRAQ, CH, DJF, BL, ICM, and JAMR are employees of Afon Technology, and MSC is the chief executive officer of Afon Technology.

Auteurs

Stephen Charles Bain (SC)

Joint Clinical Research Facility, Institute of Life Science 2, Swansea University, Swansea, UK.
Diabetes Research Group, Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK.

Stephen Luzio (S)

Diabetes Research Group, Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK.

Consuelo Handy (C)

Afon Technology, Monmouthshire, UK.

Daniel J Fowles (DJ)

Afon Technology, Monmouthshire, UK.

Bradley Love (B)

Afon Technology, Monmouthshire, UK.

Kathie Wareham (K)

Joint Clinical Research Facility, Institute of Life Science 2, Swansea University, Swansea, UK.

Lucy Barlow (L)

Joint Clinical Research Facility, Institute of Life Science 2, Swansea University, Swansea, UK.

Gareth J Dunseath (GJ)

Diabetes Research Group, Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK.

Joel Crane (J)

Diabetes Research Group, Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK.

Isamar Carrillo Masso (IC)

Afon Technology, Monmouthshire, UK.

Julia A M Ryan (JAM)

Afon Technology, Monmouthshire, UK.

Mohamed Sabih Chaudhry (MS)

Afon Technology, Monmouthshire, UK.

Classifications MeSH